CLINICAL BENEFITS OF PROBIOTIC SUPPLEMENTATION IN INFLAMMATORY BOWEL DISEASE TREATMENT: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Abstract INTRODUCTION Inflammatory bowel disease (IBD) affects about 7 million people worldwide, including 3 million adults in the United States, where it affects 1.3% of the adult population. The treatment costs for IBD can reach up to $23,000 annually, mainly due to the need for biologics and anti-inflammatory therapies. Probiotics have gained attention as a promising, low-cost addition to standard IBD treatments to reduce flare-ups and provide fewer emergency visits. ANALYSIS GOAL Our study evaluated the impact of adding probiotics to standard IBD therapy by analyzing published RCTs from four different perspectives: efficacy of probiotics, maintenance of remission, adverse events, and quality of life metrics, if available. RESEARCH METHODS A comparative analysis of 22 selected RCTs and controlled trials from PubMed was conducted, focusing on probiotics added to standard treatments for Crohn’s disease and ulcerative colitis, with studies published by October 2024. RESULTS 22 randomized controlled trials (RCTs) were included, assessing various probiotic strains and their effects on IBD patients. Among the selected studies, 17 trials (77.2%) demonstrated that adding probiotics to standard therapy effectively induced remission and reduced flare-up rates in patients with inflammatory bowel disease (IBD). A) Therapeutic Efficacy: Trials using probiotics like VSL#3, Bifico, and Escherichia coli Nissle 1917 showed marked reductions in CDAI/UCAI scores, recurrence rates, and clinical relapse rates in treatment groups compared to controls. B) Induction and Maintenance of Remission: Multiple studies observed a remission induction in treatment groups vs. placebo. C) Adverse Events: The incidence of adverse events was generally low, with most reporting no serious adverse effects. Some studies noted mild gastrointestinal symptoms, such as bloating and discomfort (e.g., Bibiloni et al. with VSL#3). D) Quality of Life: Probiotic therapy also improved the quality of life in patients with mild to moderate ulcerative colitis. CONCLUSION Probiotics given in combination with standard therapy in IBD are effective in decreasing disease activity rates and reducing remission rates. No significant adverse reactions to probiotics were noticed.